Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma

Table 2 Follow-up categories with echocardiography parameters

Follow-up category	Patients with ALL	Patients with OSC	Total population
Follow-up category	N (mean FS ± SD)	N (mean FS ± SD)	N (mean FS ± SD)	Decreased not decreased FS, N¹	OR (95% CI) ²
At the diagnosis	358	29	387
At the diagnosis	41.5 ± 6.1	39.6 ± 4.4	41.4 ± 6.0
< 1 yr. from diagnosis¹	275	5	280	104 \| 83	1.0
< 1 yr. from diagnosis¹	40.4 ± 6.1	40.2 ± 5.3	40.4 ± 6.1	104 \| 83	1.0
1–2 yr. from diagnosis	46	3	49	19 \| 10	1.5 (0.6–3.4)
1–2 yr. from diagnosis	41.4 ± 6.0	39.9 ± 2.3	41.3 ± 5.9	19 \| 10	1.5 (0.6–3.4)
End of the treatment	287	28	315	105 \| 98	0.9 (0.6–1.3)
End of the treatment	40.0 ± 5.6	38.4 ± 6.3	39.9 ± 5.7	105 \| 98	0.9 (0.6–1.3)
2–5 yr. from diagnosis	229	35	264	77 \| 73	0.8 (0.5–1.3)
2–5 yr. from diagnosis	40.4 ± 5.7	38.1 ± 5.2	40.1 ± 5.7	77 \| 73	0.8 (0.5–1.3)
5–10 yr. from diagnosis	265	36	301	70 \| 76	0.7 (0.5–1.1)
5–10 yr. from diagnosis	40.1 ± 5.5	40.3 ± 5.6	40.1 ± 5.5	70 \| 76	0.7 (0.5–1.1)
10–15 yr. from diagnosis	133	19	152	24 \| 36	0.5 (0.3–1.0)
10–15 yr. from diagnosis	40.4 ± 5.4	39.9 ± 5.2	40.3 ± 5.3	24 \| 36	0.5 (0.3–1.0)
> 15 yr. from diagnosis	24	8	32	5 \| 3	1.3 (0.3–5.7)
> 15 yr. from diagnosis	37.6 ± 7.5	40.7 ± 6.1	38.4 ± 7.2	5 \| 3	1.3 (0.3–5.7)

The decrease of FS was calculated patient by patient in every category compared to the individual value at diagnosis if these data were available. ¹ Number of patients with a decreased FS per number of patients with a not decreased FS. ² Compared to the second category. Abbreviations: CI, confidence interval; FS, left ventricular fractional shortening; OR, odds ratio; N, number; SD, standard deviation

ISSN: 1471-2407